Abstract: Objective To find out about myocarditis induced by gefitinib in order provide a reference for clinical safe medication. Methods The diagnostic and therapeutic process of a patient with myocarditis induced by gefitinib was reviewed. Related literature was retrieved to explore the mechanism of and management strategies for gefitinib-induced myocarditis. Results After more than three months of treatment with gefitinib, the patient developed chest tightness, dyspnea, and hemoptysis. Gefitinib-induced myocarditis was suspected. The drug was immediately withdrawn before symptomatic treatments including fluid resuscitation, diuresis, and myocardial nutritional support were offered. The patient's symptoms subsequently improved. Conclusion Adverse reactions such as myocarditis should be monitored during the use of gefitinib. Enhanced surveillance, early identification, and prompt interventions are required.

Key words: Gefitinib, Non-Small Cell Lung Cancer, Myocarditis, Adverse Drug Reactions